HealthInvest Partners AB Has $7.39 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

HealthInvest Partners AB grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.0% in the third quarter, HoldingsChannel.com reports. The fund owned 7,028 shares of the biopharmaceutical company’s stock after acquiring an additional 135 shares during the quarter. Regeneron Pharmaceuticals accounts for 3.5% of HealthInvest Partners AB’s holdings, making the stock its 11th biggest position. HealthInvest Partners AB’s holdings in Regeneron Pharmaceuticals were worth $7,388,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in REGN. SteelPeak Wealth LLC increased its stake in Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 692 shares in the last quarter. Atria Investments Inc increased its position in Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after buying an additional 941 shares in the last quarter. Mizuho Securities USA LLC raised its stake in Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after buying an additional 51,162 shares during the period. Tri Locum Partners LP boosted its holdings in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after acquiring an additional 8,949 shares in the last quarter. Finally, Tidal Investments LLC grew its stake in Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after acquiring an additional 711 shares during the period. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on REGN. BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Oppenheimer dropped their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Finally, Wolfe Research started coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded up $0.45 during mid-day trading on Thursday, hitting $743.80. The stock had a trading volume of 22,654 shares, compared to its average volume of 532,948. Regeneron Pharmaceuticals, Inc. has a 52 week low of $736.01 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business has a fifty day moving average price of $961.76 and a 200-day moving average price of $1,030.14. The firm has a market cap of $81.74 billion, a P/E ratio of 18.40, a PEG ratio of 2.81 and a beta of 0.15.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.